An Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 03 Nov 2017
At a glance
- Drugs NKTR 214 (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms EXCEL
- Sponsors Nektar Therapeutics
- 30 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2018.
- 30 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.
- 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History